GALDERMA

Sculptra® ACTIVATE SKIN POWER

Naturally rebuild skin's own collagen, for long-lasting results

HCP BROCHURE FOR FACE & BODY





FDA מאושר

*The first PLLA launched in the market. **The only collagen biostimulator with primary indication in IFU for face and body usages in some regions.

COLLAGEN, THE SECRET BEHIND A FIRM AND YOUTHFUL SKIN

COLLAGEN IS A KEY COMPONENT FOR HEALTHY AND YOUTHFUL SKIN.

It is one of the most abundant proteins in the body which helps in maintaining skin's shape and firmness.^{1,2}

BY THE AGE OF 45, UP TO 25% OF COLLAGEN IS LOST.³



As we age, skin will wrinkle and sag as a result of the accelerated and progressive loss and fragmentation of collagen fibres.⁴⁻⁶

In the aging face, the development of wrinkles and furrows reflects the dynamic, cumulative effects of time on the skin, soft tissues, and deep structural components of the face.⁷



RESTORE OVERALL SKIN SHAPE AND FIRMNESS WITH BIOSTIMULATORS

THE VISIBLE SIGNS OF FACIAL AGING ARE LINKED TO THE CUTANEOUS AGING CHANGES SEEN THROUGHOUT THE REST OF THE BODY.8

Although the aging changes in the face are often the most apparent ...⁹





Factors such as weight loss and post-pregnancy may favour the loss of skin elasticity and increase skin sagging.¹⁰

Biostimulators, such as poly-L-lactic acid (PLLA), may be used not only for facial rejuvenation but also for the treatment of non-facial areas to correct skin laxity and for body contouring.¹¹

SCULPTRA®: More than just Another filler

SCULPTRA® ADDRESSES THE UNDERLYING CAUSE OF FACIAL AGING AND STIMULATES THE PRODUCTION OF TYPE 1 COLLAGEN.*^{12,13}



Adapted from Goldberg D, et al. 2013¹³

BY STIMULATING THE PRODUCTION OF COLLAGEN TYPE 1, SCULPTRA® CAN RESTORE SKIN FIRMNESS, QUALITY AND RADIANCE.^{13,14,17}

*The increase in the levels of type 3 collagen did not reach statistical significance.¹³



SCULPTRA®'S EFFECTS BEGIN DEEP UNDER THE SKIN

Sculptra[®] is the *original* and *unique* injectable collagen biostimulator containing microparticles of PLLA.^{13,18}



PLLA microparticles are injected into the deep dermis



PLLA particles recruit fibroblasts



The fibroblasts deposit collagen which helps in reinforcing the skin's inner structure

PLLA works deep within the skin to stimulate the natural replacement of lost collagen.*^{13,19}

SCULPTRA® TRIPLE ACTION FOR THE FACE & BODY

gen is accompanied only by a mild

Improves skin structure and quality¹⁴⁻¹⁶

Improves skin firmness^{15,17}

Restores skin support by increasing the thickness of the dermis¹⁹

*Skin biopsies demonstrate that this formation c controlled tissue response.¹³

SCULPTRA® IS THE KEY TO FIRMER AND REJUVENATED AREAS

SCULPTRA® GRADUALLY REBUILDS THE SKIN'S STRUCTURAL FOUNDATION^{14,19}

Improved skin elasticity and overall skin quality and radiance following the increase in collagen levels¹⁴



SCULPTRA® TREATMENTS REJUVENATE AND IMPROVE SKIN QUALITY

GLOBAL EFFECT OF REPEATED INJECTIONS OF PLLA ON SKIN QUALITY[†] AFTER 12 MONTHS¹⁴



P=poly-L-lactic acid treatment

S=saline treatment

*=statistical significance

Adapted from Bohnert K. et al. 2019¹⁴

SCULPTRA®: PROVEN EFFICACY FOR MORE THAN 2 YEARS



GRADUAL, NATURAL-LOOKING RESULTS THAT LAST^{20,21}



Post-treatment Follow-up Time Point

Adapted from Narins RS, et al. 2010²⁰

IMPROVEMENT IN THE APPEARANCE OF WRINKLES UP TO AT LEAST 25 MONTHS AFTER LAST TREATMENT^{20,21}

*p<0.001 vs baseline. *p<0.001 vs human collagen ‡Only subjects treated with Sculptra® (n = 106) were included in long-term surveillance phase.

SCULPTRA® INJECTION AREAS FACE

SCULPTRA® INJECTION AREAS*22



Sculptra[®] should be injected into the deep dermis (areas marked in green)

SCULPTRA® INJECTION AREAS TO AVOID^{*22}



Sculptra[®] should not be used in these areas as the dermis is thin (areas marked in red)



SUPPORT LOSS²³

Injection technique: bolus Device: needle 24G - 26G ½ Injection depth: supraperiosteal Volume: 0.1 mL - 0.3 mL per point



FAT LOSS²³

Injection technique: fan technique (entry through preauricular angle or mandibular angle) **Device:** cannula 23G – 25G **Injection depth:** subcutaneous **Volume:** 0.2 mL per cm²



SKIN LAXITY²³

Injection technique: retroinjection Device: needle 24G - 26G Injection depth: subdermical Volume: 0.02 mL per retroinjection

*Common injection and procedure-related side effects usually resolve spontaneously within 2 to 7 days and include injection site pain, localised swelling, tenderness, redness, itching, and bruising.^{20,24}

SCULPTRA® INCREASES Skin firmness and delays The normal course of Sagging in the aging face.



Before

ELISSA, 49



45 days after 2nd sessions



25 months after treatment

Actual patient. Individual results may vary. Treated with 5 vials of Sculptra[®], 3 sessions.



Before



8 months after treatment

STEWART, 54



7 months after treatment

Actual patient. Individual results may vary. Treated with 3 vials of Sculptra[®], 3 sessions.

Actual patient. Individual results may vary. Treated with 5 vials of Sculptra[®], 3 sessions.

© Dr Linda Eve. Pictures are reproduced with permission.

SCULPTRA® POTENTIAL NON-FACIAL INJECTION AREAS*

Sculptra[®] has a safety and efficacy profile extensively evaluated in nearly 30 studies for body usage.^{10,19,25-51}



SCULPTRA® INJECTION DEPTH FOR NON-FACIAL AREAS

Superficial subcutaneous tissue.

The correct injection depth for non-facial treatment with Sculptra® is the superficial subcutaneous tissue.⁵²

SCULPTRA® NON-FACIAL INJECTION AREAS AND OUTCOMES





IMPROVEMENT IN THE APPEARANCE OF SKIN LAXITY IN THE ARMS¹⁹





Before

ARMS OF A 72-YEAR-OLD WOMAN

Actual patient. Individual results may vary.

Treated with 2 monthly sessions of Sculptra® (1 vial per session).

3 months after



REDUCTION OF SAGGING SKIN IN THE ABDOMEN¹⁹





Before

ABDOMEN OF A 43-YEAR-OLD WOMAN

Actual patient. Individual results may vary. Treated with 1 vial of Sculptra®.



REDUCTION OF SAGGING SKIN IN THE BUTTOCKS¹⁹



BUTTOCKS OF A 34-YEAR-OLD WOMAN

Actual patient. Individual results may vary.

Treated with 3 monthly sessions (1 vial per session) of Sculptra®

Before

4 months after

SCULPTRA®: HIGH PATIENT SATISFACTION FOR MORE THAN 2 YEARS

AT 25 MONTHS

HIGH SATISFACTION*53

LONG-LASTING IMPROVEMENT in the appearance of wrinkles⁺²¹

IN MORE THAN 8 OUT OF 10 PATIENTS

*81% of patients rated their results as «improved» to «excellent improvement» at 25 months.⁵² +86% of patients continued to show IGE scores of improvement up to 25 months after the last treatment.²⁰



Follow the recommended reconstitution protocol



Ensure that the environment is sterile



Inject at the appropriate depth



Inject the appropriate volume



Massage the area immediately after the treatment

RECONSTITUTION PROTOCOL FOR FACIAL AREAS*

The recommended two-step reconstitution protocol for immediate Sculptra[®] use:⁺

- Add 5 mL sterile water for injection and shake vigorously for about 1 minute, until homogeneous suspension is achieved.
- 2

Add additional 3 mL of sterile water for injection and shake again until suspension is homogeneous.

To make the injection more comfortable, add 2 mL of 2% lidocaine to the solution immediately before injecting.



Prepare 4 syringes of 2.5 mL (2 per side)

Use cannula 22*70 or 22*50 or 25g needle

THE INCIDENCE OF NODULES IS BELOW 1% WHEN USING THE CORRECT RECONSTITUTION METHOD AND INJECTION TECHNIQUE.¹⁶

*Common injection and procedure-related side effects usually resolve spontaneously within 2 to 7 days and include injection site pain, localised swelling, tenderness, redness, itching, and bruising.⁷¹⁷

[†]Global indication (except Brazil and US).

¹Adding 5 mL first, followed by 3 mL, provides extra space within the vial in the first stage for vigorous shaking.

RECONSTITUTION PROTOCOL FOR **NON-FACIAL AREAS***

The recommended two-step reconstitution protocol for immediate Sculptra[®] use:⁺

- 1 Add 5 mL sterile water for injection and shake vigorously for about 1 minute, until homogeneous suspension is achieved.
- 2 Add additional 3 mL of sterile water for injection and shake again until suspension is homogeneous.
- Aspirate the solution to syringe of 20 mL. Add 10 mL of sterile water for injection.
- 4 To make the injection more comfortable, add 2 mL of 2% lidocaine to the solution immediately before injecting.
- 5 Solution 1: Prepare 4 syringes of 5 mL syringe Solution 2: Prepare 8 syringes of 2.5 mL syringe
 - Use cannula of 22*70 or 22*50

6



SCULPTRA® REBUILDS THE SKIN'S STRUCTURAL FOUNDATION

NOT ANOTHER FILLER

The original and unique injectable collagen biostimulator containing microparticles of biocompatible PLLA.^{13,18}

THE KEY TO FIRMER AND REJUVENATED SKIN

Increases skin firmness and delays the normal course of sagging in the aging face.^{15,17}

Increases skin elasticity and improves overall skin quality and radiance following the increase in collagen levels 12 months after last treatment.¹⁴

PROVEN EFFICACY FOR MORE THAN 2 YEARS

Gradual and long-lasting results: improvement in the appearance of wrinkles up to at least 25 months after last treatment.^{20,21,53}

- HIGH PATIENT SATISFACTION FOR MORE THAN 2 YEARS

In more than 8 out of 10 patients.⁵³

SCULPTR

REFERENCES:

- Aziz J, et al. Skin Pharmacol Physiol. 2016;29(4):190-203. Farage MA, et al. Adv Wound Care (New Rochelle). 2013;2(1):5-10. Shuster S, et al. Br J Dermatol. 1975;93:639-643. Quan T, Fisher GJ. Gerontology. 2015;61(5):427-434. Varani J, et al. Am J Pathol. 2006;168(6):1861-1868. Fisher GJ, et al. Arch Dermatol. 2008;144(5):666-672. Coleman SR, et al. Aesthetic Surgery Journal. 2006;26(1):S4-S9. Sparavigna A. Plast Aesthet Res. 2020;7:14. Elament F et al. Clin Cosmet Investign Dermatol. 2013;6:221-232

- 5. 6. 7. 8. 9. 10.

- Sparavigna A. *Plast Aesthet Res.* 2020;7:14. Flament F, *et al. Clin Cosmet Investig Dermatol.* 2013;6:221-232. Da Cunha MG, *et al. Surg Cosmet Dermatol.* 2016;8(4)322-327. Haddad A, *et al. Surg Cosmet Dermatol.* 2016;8(1)60-71. Fitzgerald R, *et al. Aesthet Surg J.* 2018;38(suppl_1):S13-S17. Goldberg D, *et al. Dermatol Surg.* 2013;39(6):915-922. Bohnert K, *et al. Plast Reconstr Surg.* 2019;45(5):718-724. Haddad A, *et al. J Drugs Dermatol.* 2019;18(9):929-935. Data on File (MA-48830). Hexsel D, *et al. Dermatol Surg.* 2020;46(8): 1122-1124. Lacombe V. *Facial Plast Surg.* 2009;25(2):95-99. Mest DR, Humble G. *Dermatol Surg.* 2006;32(11):1336-1345. Narins RS, *et al. J Am Acad Dermatol.* 2010;62(3):448-462. Brandt FS, *et al. Aesthet Surg J.* 2011;31(5):521-528. Redaelli A, *et al. JDD.* 2014;13(9):1057-1066. Sculptra. Instructions for Use Brazil.

- 11.
 12.
 13.
 14.
 15.
 16.
 17.
 18.
 19.
 20.
 21.
 22.

- Sculptra. Instructions for Use Brazil. Lowe NJ, et al. Dermatol Surg. 2009;35(1):344–349. 23. 24. 25. 26. 27.
- Mazzuco R. *J Cosmet Dermatol.* 2020;19(5):1165-1171. Mazzuco R, *et al. Dermatol Surg.* 2020;46 Suppl 1:S86-S88.
- Kollipara R, et al. Dermatol Surg. 2020;46(12):1623-1627.

ABBREVIATIONS:

G = Gauge system; IGE = Investigator Global Evaluations; PLLA = Poly-L-lactic acid.

Sculptra and Galderma are trademarks owned by Galderma Holding S.A.

GL-SCI-2100010. Date of preparation: August 2021. This material is exclusive to Brazil, which is allowed to promote Sculptra® for body indication. 7.23

- 30.
 31.
 32.
 33.
 34.
 35.
 36.
 37.
 38.
 39.
 40.
 41.
 42.
 43.
 44.
 45.
 46.
 47.
 48.
 49.
 50.
 51.

- Lin MJ, et al. Dermatol Surg. 2020;46(3):386-394. Sola CA, Fabi SG. Dermatol Surg. 2020;46(9):1257-1258. Durairaj KK, et al. Dermatol Surg. 2019;45(9):1171-1184. Wilkerson EC, Goldberg DJ. J. Cosmet Dermatol. 2018;17(4):606-610. Jabbar A, et al. J Drugs Dermatol. 2017;16(5):489-494. Sadick NS, Arruda S. Dermatol Surg. 2017;43(2):313-315. Mazzuco R, Sadick NS. Dermatol Surg. 2016;42(3):443. Peterson JD, Kilmer SL. Dermatol Surg. 2016;42(3):443. Peterson JD, Kilmer SL. Dermatol Surg. 2016;42(3):443. Veggaar D, et al. J Drugs Dermatol. 2017;13(4):504-855. Lorenc ZP. Aesthetic Plast Reconstr Surg. 2015;136(5 Suppl):2765-281S. Vleggaar D, et al. J Drugs Dermatol. 2011;3(4):544-555. Lorenc ZP. Aesthetic Plast Surg. 2012;36(5):1222-1229. Kühne U, Imhof M. J Cutan Aesthet Surg. 2012;3(1):63-169. Coimbra DD, Amorim AGF. Surg Cosmet Dermatol. 2012;4(2):182-185. Bolton J, et al. Cosmet Dermatol. 2011;24(6):278-284. Palm MD, et al. J Consmet Laser Ther. 2010;12(6):284-287. Redaelli A, Forte R. J Cosmet Dermatol. 2009;8(4):239-248. Mazzuco R, Hexsel D. Dermatol Surg. 2009;35(8):1228-1237. Sadick NS, et al. J Cosmet Laser Ther. 2009;16(4):237-241. Schulman MR, et al. J Drugs Dermatol. 2006;5(10):1000-1001. Redaelli A. J Cosmet Dermatol. 2006;5(10):1000-1001. Redaelli A. J Drugs Dermatol. 2006;5(10):1000-1001.

- 52. 53. 54.

GALDERMA

aminep@ami.co.il 🖾 amiweb@ami.co.il 👘 🞯 🕧 משווק בלעדית ע״י אמי טכנולוגיות 🕅 🖂 Technologies 🔥 אמווק בלעדית ע״י אמי טכנולוגיות 🕅 🕲 Technologies